Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499549 | 0.92 | IGF1R (0.45) | BCHEMEN1KMT2AHDAC6HDAC3 | |
| SCHEMBL1499548 | 0.92 | IGF1R (0.45) | BCHEMEN1KMT2AHDAC6HDAC3 | |
| SCHEMBL15878029 | 0.90 | SNCA (0.53) | BCHEMEN1KMT2ASIGMAR1SMN1; SMN2 | |
| SCHEMBL12767150 | 0.90 | SNCA (0.53) | BCHEMEN1KMT2ASIGMAR1SMN1; SMN2 | |
| SCHEMBL1499341 | 0.89 | KMT2A (0.45) | BCHEMEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL1499343 | 0.89 | KMT2A (0.45) | BCHEMEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL12964819 | 0.87 | MCHR1 (0.51) | BCHEMEN1KMT2AIGF1RGAA | |
| SCHEMBL1499345 | 0.86 | HDAC6 (0.45) | BCHEMEN1KMT2ATDP1HDAC6 | |
| SCHEMBL1499348 | 0.86 | HDAC6 (0.45) | BCHEMEN1KMT2ATDP1HDAC6 | |
| SCHEMBL12760660 | 0.86 | MCHR1 (0.48) | MEN1KMT2ASIGMAR1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | BCHE 1333/4885MEN1 3393/4885KMT2A 3766/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | BCHE 1333/4885MEN1 3393/4885KMT2A 3766/4885 |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, CBR3, TP53BP1 | BCHE 1324/4885MEN1 3259/4885KMT2A 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.